MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
Mind Medicine (MindMed) (NASDAQ: MNMD), a clinical-stage biopharmaceutical company, announced the presentation of encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the company's lead product candidate for treating generalized anxiety disorder (GAD), at the ACNP 2024 Congress held from December 8-11 in Phoenix, AZ.
The presentations included two posters:
- Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with GAD, presented by Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed.
- Rapid and durable response to a single dose of MM120 (lysergide) in GAD: A dose-optimization study, presented by Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed.
The posters are available on MindMed’s Company website.
Mind Medicine (MindMed) (NASDAQ: MNMD), un'azienda biofarmaceutica in fase clinica, ha annunciato la presentazione dei dati di recupero del suo studio di Fase 2b su MM120 (lysergide D-tartrato o LSD), il principale candidato prodotto dell'azienda per il trattamento del disturbo d'ansia generalizzato (GAD), durante il Congresso ACNP 2024 che si svolgerà dall'8 all'11 dicembre a Phoenix, AZ.
Le presentazioni hanno incluso due poster:
- Disabilità funzionale e sessuale, e qualità della vita dopo una dose di MM120 (lysergide) in adulti con GAD, presentato da Paula Jacobson, Ph.D., Direttore Esecutivo, Sviluppo Clinico, MindMed.
- Risposta rapida e duratura a una singola dose di MM120 (lysergide) nel GAD: uno studio di ottimizzazione della dose, presentato da Dan Karlin, M.D., M.A., Direttore Medico, MindMed.
I poster sono disponibili sul sito web di MindMed.
Mind Medicine (MindMed) (NASDAQ: MNMD), una compañía biofarmacéutica en etapa clínica, anunció la presentación de datos adicionales de su estudio de Fase 2b sobre MM120 (lidérside D-tartato o LSD), el principal candidato de producto de la compañía para tratar el trastorno de ansiedad generalizada (GAD), en el Congreso ACNP 2024 que se llevará a cabo del 8 al 11 de diciembre en Phoenix, AZ.
Las presentaciones incluyeron dos pósters:
- Discapacidad funcional y sexual, y calidad de vida después de una dosis de MM120 (lidérside) en adultos con GAD, presentado por Paula Jacobson, Ph.D., Directora Ejecutiva, Desarrollo Clínico, MindMed.
- Respuesta rápida y duradera a una dosis única de MM120 (lidérside) en GAD: un estudio de optimización de dosis, presentado por Dan Karlin, M.D., M.A., Director Médico, MindMed.
Los pósters están disponibles en el sitio web de MindMed.
마인드 메디슨 (MindMed) (NASDAQ: MNMD)는 임상 단계의 바이오 제약 회사로, MM120(리세르지드 D-타르트레이트 또는 LSD)에 대한 Phase 2b 연구의 추가 데이터를 발표했다고 발표했습니다. 이는 회사의 주요 제품 후보로 범불안장애 (GAD) 치료에 사용됩니다. ACNP 2024 회의는 12월 8일부터 11일까지 애리조나주 피닉스에서 열립니다.
발표는 두 개의 포스터를 포함했습니다:
- GAD가 있는 성인에서 MM120(리세르지드)의 한 번의 투여 후 기능적 및 성적 장애와 삶의 질, 발표자: Paula Jacobson, Ph.D., 임상 개발 전무 이사, MindMed.
- GAD에서 MM120(리세르지드) 단일 투여에 대한 빠르고 지속적인 반응: 용량 최적화 연구, 발표자: Dan Karlin, M.D., M.A., MindMed의 최고 의료 책임자.
포스터는 MindMed의 회사 웹사이트에서 확인할 수 있습니다.
Mind Medicine (MindMed) (NASDAQ: MNMD), une entreprise biopharmaceutique en phase clinique, a annoncé la présentation de données complémentaires de son étude de phase 2b sur MM120 (lysergide D-tartrate ou LSD), le principal candidat produit de l'entreprise pour le traitement du trouble anxieux généralisé (GAD), lors du Congrès ACNP 2024 qui se tiendra du 8 au 11 décembre à Phoenix, AZ.
Les présentations comprenaient deux affiches :
- Incapacité fonctionnelle et sexuelle, et qualité de vie après une dose de MM120 (lysergide) chez des adultes atteints de GAD, présentée par Paula Jacobson, Ph.D., Directrice Exécutive, Développement Clinique, MindMed.
- Réponse rapide et durable à une dose unique de MM120 (lysergide) dans le GAD : une étude d'optimisation de la dose, présentée par Dan Karlin, M.D., M.A., Directeur Médical, MindMed.
Les affiches sont disponibles sur le site web de MindMed.
Mind Medicine (MindMed) (NASDAQ: MNMD), ein biopharmazeutisches Unternehmen in klinischer Phase, gab die Präsentation von zusätzlichen Daten aus seiner Phase 2b-Studie zu MM120 (Lysergid D-Tartrat oder LSD), dem Hauptproduktkandidaten des Unternehmens zur Behandlung von generalisierter Angststörung (GAD), auf dem ACNP 2024 Kongress bekannt, der vom 8. bis 11. Dezember in Phoenix, AZ, stattfindet.
Die Präsentationen umfassten zwei Poster:
- Funktionale und sexuelle Einschränkung sowie Lebensqualität nach einer Dosis von MM120 (Lysergid) bei Erwachsenen mit GAD, präsentiert von Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed.
- Schnelle und dauerhafte Reaktion auf eine Einzeldosis von MM120 (Lysergid) bei GAD: Eine Dosisoptimierungsstudie, präsentiert von Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed.
Die Poster sind auf der Unternehmenswebsite von MindMed verfügbar.
- Presentation of encore data from Phase 2b study of MM120 at ACNP 2024 Congress.
- MM120 shows potential for rapid and durable response in treating generalized anxiety disorder.
- None.
Details of the presentations are as follows:
Title: Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with generalized anxiety disorder
Format: Poster
Presenter: Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed
Title: Rapid and durable response to a single dose of MM120 (lysergide) in generalized anxiety disorder: A dose-optimization study
Format: Poster
Presenter: Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed
Posters are available on MindMed’s Company website.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
This press release is not sanctioned by ACNP.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211736280/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
For Medical Affairs: medaffairs@mindmed.co
Source: Mind Medicine
FAQ
What did MindMed present at the ACNP 2024 Congress?
When did MindMed present at the ACNP 2024 Congress?
What is MM120?
Who presented the data on MM120 at the ACNP 2024 Congress?
What were the topics of the posters presented by MindMed?
Where can I find the posters presented by MindMed at the ACNP 2024 Congress?
